Levoreact (Levocabastine Hydrochloride)

Levocabastine selectively blocks histamine H1 receptors in the nasal mucosa. By preventing histamine from binding, it stops the cascade that leads to blood vessel dilation and increased permeability, thereby reducing swelling, fluid secretion, and the sensory irritation that cause allergy symptoms.

The dosing regimen for Levoreact is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product label for the number of sprays per nostril and frequency of use.

Safety data for levocabastine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Levoreact.

To order Levoreact, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Levoreact’s active ingredient, levocabastine, is a selective H1‑receptor antagonist offering rapid onset of action with minimal systemic absorption. Compared with some older antihistamine sprays, it may cause fewer sedative effects and provides targeted relief directly in the nasal passages.

Levoreact should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures that could affect spray performance.

Levoreact is administered as a nasal spray. The patient gently shakes the bottle, inserts the tip into one nostril, and sprays the prescribed number of sprays while breathing in gently. The same procedure is repeated in the other nostril if directed by the prescriber.

The most serious risks include rare but severe allergic reactions such as anaphylaxis, persistent nosebleeds, and significant nasal ulceration. Users should seek immediate medical attention if they experience swelling of the face or throat, difficulty breathing, or prolonged bleeding.

Levoreact should not be used by individuals with known hypersensitivity to levocabastine or any other component of the formulation. It is also contraindicated in patients with severe nasal infection, trauma, or those currently taking monoamine oxidase inhibitors without medical supervision.